Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) have been assigned an average rating of “Buy” from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.31.

A number of research firms have recently weighed in on DRNA. Leerink Swann began coverage on Dicerna Pharmaceuticals in a research note on Tuesday, November 27th. They set an “outperform” rating and a $24.00 price target for the company. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. B. Riley raised Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $13.50 to $21.00 in a research note on Tuesday, November 6th. Cowen reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, November 6th. Finally, HC Wainwright raised their price target on Dicerna Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, October 31st.

In other news, Director Brian K. Halak sold 245,096 shares of the stock in a transaction dated Tuesday, October 30th. The stock was sold at an average price of $13.92, for a total transaction of $3,411,736.32. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Brian K. Halak sold 335,000 shares of the stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $13.33, for a total value of $4,465,550.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,144,396 shares of company stock worth $15,585,624. 19.85% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. RTW Investments LP grew its holdings in Dicerna Pharmaceuticals by 0.3% in the 2nd quarter. RTW Investments LP now owns 5,044,813 shares of the biopharmaceutical company’s stock valued at $61,799,000 after buying an additional 15,351 shares during the last quarter. EcoR1 Capital LLC lifted its position in shares of Dicerna Pharmaceuticals by 28.4% during the 3rd quarter. EcoR1 Capital LLC now owns 3,802,327 shares of the biopharmaceutical company’s stock worth $58,024,000 after buying an additional 841,180 shares during the period. BlackRock Inc. lifted its position in shares of Dicerna Pharmaceuticals by 13.8% during the 3rd quarter. BlackRock Inc. now owns 2,967,073 shares of the biopharmaceutical company’s stock worth $45,277,000 after buying an additional 359,178 shares during the period. Vanguard Group Inc. lifted its position in shares of Dicerna Pharmaceuticals by 40.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,983,272 shares of the biopharmaceutical company’s stock worth $30,265,000 after buying an additional 573,197 shares during the period. Finally, Citadel Advisors LLC raised its position in Dicerna Pharmaceuticals by 14.8% in the 3rd quarter. Citadel Advisors LLC now owns 1,950,195 shares of the biopharmaceutical company’s stock valued at $29,760,000 after purchasing an additional 251,280 shares during the last quarter. 87.20% of the stock is currently owned by institutional investors and hedge funds.

DRNA opened at $13.60 on Monday. Dicerna Pharmaceuticals has a fifty-two week low of $6.80 and a fifty-two week high of $17.98. The stock has a market cap of $870.72 million, a PE ratio of -3.72 and a beta of 2.39.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.11). Dicerna Pharmaceuticals had a negative return on equity of 63.24% and a negative net margin of 1,418.01%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.67 million. As a group, equities research analysts anticipate that Dicerna Pharmaceuticals will post -1.15 earnings per share for the current fiscal year.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Read More: Market Capitalization

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.